GCG and diabetes mellitus: Unimolecular dual and triple agonists that target glucagon and incretin hormone receptors have been shown to improve bodyweight loss, lower glucose levels, and reduce food intake in animal models of obesity and NASH, and multiple dual agonists are in clinical development for the treatment of obesity and diabetes.